Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-03

SABS vs XFOR: stock comparison and AI forecast

Sab Biotherapeutics, Inc. (SABS) and X4 Pharmaceuticals, Inc (XFOR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Biological Products, (No Diagnostic Substances)

SABS Sab Biotherapeutics, Inc.

Price
$3.30 -10.6% · 6M
Market Cap
$300M
P/E Ratio
165.0x
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Biological Products, (No Diagnostic Substances)

XFOR X4 Pharmaceuticals, Inc

Market Cap
$332M
P/E Ratio
2.3x
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

SABS · XFOR

Key facts

  • XFOR is 1.1 times larger than SABS by market capitalization ($332M against $300M).
  • XFOR trades at 2.3 times trailing earnings, SABS at 165.0 times.
  • XFOR carries 0.63 times debt per unit of equity, against 0.11 times for SABS.
  • Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricSABSXFOR
Market Cap$300M$332M
P/E Ratio165.00x2.28x
P/B Ratio1.40x2.14x
EPS$0.02$1.47
Book Value/Share$2.36$1.57
Revenue/Share–$0.09

Profitability & Margins

MetricSABSXFOR
ROIC-31.7%-37.6%
Gross Margin–66.5%
Operating Margin6571.2%-1003.9%
EBT Margin878.0%-1026.2%
Tax Rate–0.0%

Financial Health

MetricSABSXFOR
Current Ratio9.22x11.30x
Quick Ratio–11.28x
D/E Ratio0.11x0.63x
Financial Leverage1.11x1.63x
Interest Coverage-377.0x-2.9x
Working Capital$96M$199M

Cash Flow

MetricSABSXFOR
Operating Cash Flow-$54M-$84M

Operational Efficiency

MetricSABSXFOR
Asset Turnover–0.03x
Receivables Turnover–4.3x
Inventory Turnover–5.5x
Fixed Assets Turnover–78.9x
Days Sales Outstanding–85 days
Days Inventory–66 days
Payables Period–616 days
Cash Conversion Cycle–-465 days

Income Statement

MetricSABSXFOR
Total Revenue–$9M
Operating Income-$72M-$88M
R&D Expense$49M$66M
Cost of Goods Sold–$2M

Dividend & Shareholder Information

MetricSABSXFOR
Shares Outstanding91M99M
FAQ

SABS vs XFOR: stock comparison and AI forecast

Which is bigger, SABS or XFOR?

XFOR is 1.1 times larger than SABS by market capitalization ($332M against $300M).

Which is cheaper on earnings, SABS or XFOR?

XFOR trades at 2.3 times trailing earnings, SABS at 165.0 times.

Which one does Intratio's AI model rank higher, SABS or XFOR?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.